Karin Oien
Reader
Department of Oncology
University of Glasgow
United Kingdom
Biography
Dr Karin Oien is currently working as a Reader (Experimental Therapeutics).
Research Interest
Dr Oien’s pathology practice is in gastro-intestinal and liver disease, especially cancer. This is mirrored in her clinical research. Her translational and basic science has two main themes: the application of global profiling technologies to tissues for improved cancer classification, diagnosis, prediction of prognosis or treatment guidance; and the characterisation of biomarkers identified through candidate gene approaches. The aims are to identify and develop clinically useful cancer biomarkers, and to elucidate underlying biology. Current projects include: clinical trials of our algorithm for the prediction of primary site in metastatic adenocarcinoma of unknown origin; and the identification of novel biomarkers linked with outcome in pancreatic cancer.
Publications
-
Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)
-
Jones, W., Allardice, G., Scott, I., Oien, K., Brewster, D. and Morrison, D. S. (2017) Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer, 17, 85. (doi:10.1186/s12885-017-3083-1) (PMID:28143449) (PMCID:PMC5282907)
-
Wong, N. A.C.S., Adamczyk, L. A., Evans, S., Cullen, J., Oniscu, A. and Oien, K. A. (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology, 71(1), pp. 34-41. (doi:10.1111/his.13194) (PMID:28226180)
